Showing results (31-40 of 58) with videos related to
Sort By:
Pageof 6
Brain Pathology (Zurich, Switzerland)|March 5, 2013
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous systemAditya Raghunathan, Khalida Wani, Terri S Armstrong, et al.Cancers|November 13, 2021
Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade OutcomesRobert A Szczepaniak Sloane, Michael G White, Russell G Witt, et al.Cell Reports|July 21, 2021
Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategyChristopher J Terranova, Ming Tang, Mayinuer Maitituoheti, et al.Frontiers in Immunology|May 15, 2025
Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experienceMadeline B Torres, Cheuk Hong Leung, Marianne Zoghbi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable MelanomaElizabeth M Burton, Denái R Milton, Michael T Tetzlaff, et al.Oncoimmunology|November 15, 2021
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanomaMichael G White, Robert Szczepaniak Sloane, Russell G Witt, et al.Cancer Cell|September 3, 2013
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastomaKrishna P L Bhat, Veerakumar Balasubramaniyan, Brian Vaillant, et al.The Journal of Experimental Medicine|September 30, 2024
An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axisIan W Folkert, William A Molina Arocho, Tsun Ki Jerrick To, et al.Nature|July 19, 2023
Diverse clonal fates emerge upon drug treatment of homogeneous cancer cellsYogesh Goyal, Gianna T Busch, Maalavika Pillai, et al.Cancer Cell|May 10, 2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Daniel H Johnson, Noha Abdel-Wahab, et al.Pageof 6